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DMBA induced rat mammary tumors were used to study the association of tyrosine protein kinase activity 
with tumor growth. Pharmacological manipulations of blood prolactin level, by perphenazine and bromo- 
criptine, were used to stimulate or arrest umor growth, respectively. During perphenazine treatment, a 
2-3-fold increase in membranal tyrosine protein kinase activity, measured with angiotensin II as substrate, 
preceded the 34fold increase in tumor area. At the same time the cAMPdependent protein kinase activity, 
measured with kemptide as substrate, did not change. 
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1. INTRODUCTION 
Tyrosine protein kinases are enzymes that 
phosphorylate tyrosine residues of protein 
substrate. These protein kinase activities have been 
found in association with retrovirus transforming 
proteins [ 1,2]. Moreover, a number of polypeptide 
growth factor receptors including those for epider- 
mal growth factor [3], platelet-derived growth fac- 
tor [4], insulin [5] and somatomedin C [6] 
demonstrate tyrosine protein kinase activity. These 
results suggest a relationship between tyrosine pro- 
tein kinase activity and the control of cell pro- 
liferation, although the exact nature of such a rela- 
tionship is unknown. Less information is available 
on the role of tyrosine protein kinase in tissue 
growth, In a recent report, tyrosine protein kinase 
activity was shown to increase during em- 
bryogenesis 171. The DMBA-induced mammary 
tumor may serve as an excellent model for such 
studies, as its growth rate is easily manipulated by 
hormones. Estrogens [8] and prolactin [9] 
Abbreviation: DMBA, 7,12-dimethylbenz(a)anthracene 
stimulate its growth, while ovariectomy [8], an- 
tiestrogens [lo] and drugs which decrease plasma 
prolactin level cause growth arrest or regression of 
the tumors [ 111. In the DMBA-induced mammary 
tumor as well as in the mammary gland and uterine 
tissue, changes in growth rate induced by hor- 
mones were associated with parallel changes in 
CAMP-independent quercetin-inhibited protein 
kinase activity fll-141. We have recently shown 
the presence of tyrosine protein kinase activity in 
the membranes of these tumors [15]. This activity 
was inhibited by quercetin, similar to the CAMP- 
independent protein kinase activity that we 
measured previously in normal and malignant rat 
mammary tissues. In this report we describe the 
association between the membranal tyrosine pro- 
tein kinase activity and the growth process induced 
by prolactin in these tumors. 
2. MATERIALS AND METHODS 
r3P]ATP was obtained from Nuclear Research 
Center (Negev, Israel). DMBA, quercetin, CAMP, 
theophylline, angiotensin II and kemptide from 
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Sigma. Perphenazine from Schering Corp. 
(Kanilword, NJ). Bromocryptine was a generous 
gift by Dr E. Flukiger, Sandoz (Basel, 
Switzerland). 
2.1. Induction of tumors and preparation of 
membranes 
Rat mammary tumors were induced by DMBA 
and their area was measured as described earlier 
[ 141. Tumor growth arrest was achieved by daily 
injection of 0.5 mg bromocryptine for lo-14 days. 
Rapid tumor growth was then induced by daily in- 
jection of 1.0 mg perphenazine which causes an 
elevation of the plasma prolactin (Levy et al., sub- 
mitted). The tumors were removed, frozen and 
crude membrane fractions were prepared as 
described [13]. The membranes were dispersed in 
the homogenization buffer containing 0.5% Triton 
X-100 and were used for protein kinase assays. 
2.2. Protein kinase activity assays 
Tyrosine kinase activity was measured by using 
angiotensin II as the peptide substrate as described 
previously [15,16]. CAMP-dependent protein 
kinase activity was measured using kemptide as the 
peptide substrate ssentially as described by Kemp 
[ 171. This activity was calculated by subtracting the 
phosphorylation obtained in the presence of 
CAMP from that obtained in its absence. 
3. RESULTS AND DISCUSSION 
The effects of CAMP and quercetin on the 
phosphorylation of both peptide substrates by the 
tumor membranes were checked (fig.1). Cyclic 
AMP increased the phosphorylation of kemptide 
threefold while quercetin had no effect on this ac- 
tivity (fig.la). In contrast, the phosphorylation of 
angiotensin II was not affected by CAMP but was 
inhibited by quercetin, in the presence or absence 
of CAMP (fig.lb). The differential effects of 
CAMP and quercetin on the two activities indicate 
that the CAMP-dependent protein kinase does not 
interfere with the measurement of the tyrosine pro- 
tein kinase or vice versa. 
The two membranal protein kinase activities 
were measured during growth arrest (bromocryp- 
tine treatment), or on different days of tumor 
growth induction by perphenazine (fig.2). An 
almost threefold increase in tyrosine protein kinase 
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Fig. 1. The effect of quercetin and CAMP on angiotensin 
II and kemptide phosphorylation. Peptide phosphoryla- 
tion was measured as described in section 2.2. Quercetin, 
CAMP or both were added at the indicated concentra- 
tions. (a) Tyrosine protein kinase activity. (b) CAMP- 
dependent protein kinase. The results are the mean f SE 
of 3 experiments. 
activity was evident immediately after the first day 
of perphenazine treatment, and the activity re- 
mained at the higher level during the five days of 
the treatment. At the same time the CAMP- 
dependent protein kinase activity did not change 
significantly. The tumor area changed at a slower 
rate, and an increase of two- to three-fold, that 
was significant by one-way ANOVA, was evident 
only after four days. These results indicate that ac- 
tivation of tyrosine protein kinases in tumor mem- 
branes, but not CAMP-dependent protein kinase, 
is an early event in the hormone-induced growth 
process and suggest hat the enzyme activity may 
lead to the growth. The tyrosine protein kinase ac- 
tivity probably represents an important part of the 
CAMP-independent and quercetin-inhibited pro- 
tein kinase activity which we previously found to 
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Fig.2. Stimulation of tumor growth, tyrosine protein 
kinase activity and CAMP-dependent protein kinase 
activity during perphenazine treatment. Tumor area at 
the end of bromocriptine treatment (day 0) was defined 
as - 1 (relative area) and was followed during the next 
days of perphenazine treatment (A---A). The two 
protein kinase activities were measured as described in 
section 2.2. (M) Tyrosine protein kinase activity; 
(C---o) CAMP-dependent protein kinase activity. The 
results are the mean + SE of 4-8 tumors. * denotes 
significant difference from day 0 (p < 0.05 by one-way 
ANOVA and Newman Keuls procedure). 
be associated with growth of the rat mammary 
tumors ([14] and Levy et al., submitted). 
Tyrosine kinase activity is associated with 
mitogens and growth factor receptors [3-61. The 
presence of insulin [18] and EGF [19] receptors in 
the membrane of mammary tumors has been 
reported previously. Other tyrosine protein kinases 
such as some oncogen products, may also be 
located in the mammary tumor membrane [20,21] 
and thereby contribute to the enzymatic activity 
measured in this study. 
Although the involvement of tyrosine protein 
kinase activity in the growth process was suggested 
quite some time ago, there are surprisingly few 
reports correlating the two phenomena in vivo. 
The activity of tyrosine protein kinase in the sea 
urchin embryo was markedly increased during ear- 
ly embryonic development [7]. Similar effects were 
found in psoriatic skin. The increase in specific ac- 
tivity of tyrosine kinase in the psoriatic plaque cor- 
responded well with an increase in mitotic index in 
this tissue as compared to normal skin [22]. On the 
other hand tyrosine protein kinase was found in a 
variety of tissues, some of which are known to 
grow slowly or not at all [23,24]. For example, 
higher tyrosine protein kinase activity in resting 
lymphocytes than in proliferating normal or 
leukemic blood cells was reported recently [23]. 
High tyrosine kinase activity was also shown in the 
particulate fraction from non-proliferating 
anuclear cells, such as platelets and red blood cells 
[24]. To the best of our knowledge this is the first 
report relating tyrosine kinase activity to the in 
vivo induction of tumor growth by hormones. The 
exact mechanism by which tyrosine kinases are in- 
volved in growth regulation is not known. It was 
suggested that these enzymes affect several 
metabolic pathways which might be related to each 
other. Among them are the phosphatidylinositol 
pathway [25], DNA and protein synthesis. Two re- 
cent reports link, albeit not directly, S6 
phosphorylation and tyrosine kinase activity of the 
src and abl oncogen protein products [26,27]. The 
phosphorylation of this ribosomal protein, S6, was 
found to be involved in the regulation of protein 
synthesis. Another study suggests the nuclear en- 
zymatic activity of topoisomerase as substrate for 
cytosolic tyrosine kinase in liver [28]. These and 
other reports challenge our findings and are 
presently under active study. 
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